Essa Pharma INC Form 4 insider transactions

ESSA Pharma's President and CEO, David Parkinson, reported the disposal of all his common shares as part of the company's acquisition by Xeno Acquisition Corp.

ESSA Pharma Inc.'s Chief Financial Officer, David S. Wood, reported the disposal of 33,343 common shares following a business combination.

ESSA Pharma Inc. director Franklin M. Berger reported the sale of all his common shares following the company's acquisition by Xeno Acquisition Corp. for cash and contingent value rights.

ESSA Pharma Inc. Director Richard Glickman disposed of 43,240 common shares as part of a business combination agreement where the company was acquired for cash and contingent value rights.

ESSA Pharma Director Scott Requadt reported the disposition of 30,002 common shares as part of the company's acquisition by Xeno Acquisition Corp. for cash and contingent value rights.

ESSA Pharma Director John Alexander Martin reported the disposition of all his common shares following the company's acquisition by Xeno Acquisition Corp. for cash and contingent value rights.

Marella Thorell, a director of ESSA Pharma Inc., reported the disposition of shares as part of the company's acquisition by Xeno Acquisition Corp.

BVF Partners and affiliated entities have fully divested their common stock holdings in ESSA Pharma Inc. as part of a business combination agreement effective October 9, 2025.

BVF Partners and affiliated entities exercised pre-funded warrants to acquire 2.92 million shares of ESSA Pharma common stock, increasing their beneficial ownership.

Biotech Growth N.V., a subsidiary of BB Biotech AG, has sold a significant portion of its holdings in ESSA Pharma Inc.

Peter Virsik, COO of ESSA Pharma Inc., sold 694 common shares at a weighted average price of $6.03 under a pre-arranged 10b5-1 trading plan.

Peter Virsik, Chief Operating Officer of ESSA Pharma Inc., sold 694 common shares at a weighted average price of $6 per share on September 9, 2024, under a pre-arranged 10b5-1 trading plan.

Peter Virsik, Chief Operating Officer of Essa Pharma Inc., sold 2,082 common shares at a weighted average price of $6.03 per share on September 3, 2024, under a pre-arranged 10b5-1 trading plan.

Peter Virsik, COO of Essa Pharma Inc., sold 694 common shares at a weighted average price of $6.95 on May 6, 2024, under a pre-arranged 10b5-1 trading plan.

Director Richard Glickman reports a transaction involving ESSA Pharma Inc. shares and options.

Peter Virsik, COO of ESSA Pharma Inc., sold 694 common shares at a weighted average price of $7.94 on April 5, 2024, under a pre-arranged 10b5-1 trading plan.

Sanford Zweifach, a director of ESSA Pharma Inc., reported acquiring 50,000 options exercisable for common shares on March 25, 2024.

Director Marella Thorell reports acquisition of 50,000 options in ESSA Pharma Inc.

Director Gary Sollis reports acquiring 50,000 options in ESSA Pharma Inc.

Director Scott Requadt reports acquiring 50,000 options of ESSA Pharma Inc.

Lauren Merendino, a director of ESSA Pharma Inc., acquired 25,000 options on March 25, 2024.

John Alexander Martin, a director of Essa Pharma Inc., acquired 50,000 options exercisable for common shares on March 25, 2024.

Director Philip W. Kantoff reports acquisition of 50,000 options in ESSA Pharma Inc.

Director Richard Glickman reports acquiring 70,000 options of ESSA Pharma Inc. on March 25, 2024.

Director Franklin Berger reported acquiring 50,000 options of Essa Pharma Inc. on March 25, 2024.

ESSA Pharma's Chief Financial Officer, David S. Wood, reported the acquisition of 110,000 stock options.

Chief Operating Officer Peter Virsik reports the acquisition of 110,000 stock options in ESSA Pharma Inc.

ESSA Pharma Inc. CEO David Parkinson reports the acquisition of 350,000 stock options on March 25, 2024.

Alessandra Cesano, Chief Medical Officer of ESSA Pharma Inc., reports the acquisition of 200,000 stock options on March 25, 2024.

Peter Virsik, Chief Operating Officer of ESSA Pharma Inc., sold 694 common shares at an average price of $8.98 on March 5, 2024, under a pre-arranged 10b5-1 trading plan.